All Stories

  1. Real-world studies provide reliable comparisons of disease modifying therapies in MS – Yes

    Article • Multiple Sclerosis Journal, September 2019, SAGE Publications

    Dr Tomas Kalincik

  2. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Article • Multiple Sclerosis Journal, August 2019, SAGE Publications

    Dr Tomas Kalincik

  3. The MSBase registry: Informing clinical practice

    Article • Multiple Sclerosis Journal, May 2019, SAGE Publications

    Dr Tomas Kalincik

  4. Where there is inflammation, treatment may reduce disability progression – Yes

    Article • Multiple Sclerosis Journal, October 2018, SAGE Publications

    Dr Tomas Kalincik

  5. Comparisons of therapies in different scenarios help complete the puzzle

    Article • Multiple Sclerosis Journal, April 2018, SAGE Publications

    Dr Tomas Kalincik

  6. Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data

    Article • Brain, March 2018, Oxford University Press (OUP)

    Dr Tomas Kalincik

  7. Cognitive clinico-radiological paradox in early stages of multiple sclerosis

    Article • Annals of Clinical and Translational Neurology, December 2017, Wiley

    Dr Tomas Kalincik

  8. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

    Article • Multiple Sclerosis Journal, August 2017, SAGE Publications

    Dr Tomas Kalincik

  9. Familial mesial temporal lobe epilepsy and the borderland of déjà vu

    Article • Annals of Neurology, July 2017, Wiley

    Dr Tomas Kalincik, Dr Piero Perucca

  10. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

    Article • Autoimmunity Reviews, June 2017, Elsevier

    Dr Tomas Kalincik

  11. Stop inflammation and you stop neurodegeneration in MS – NO

    Article • Multiple Sclerosis Journal, May 2017, SAGE Publications

    Dr Tomas Kalincik

  12. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

    Article • The Lancet Neurology, April 2017, Elsevier

    Professor Tjalf Ziemssen, Dr Tomas Kalincik

  13. Treatment decisions in multiple sclerosis — insights from real-world observational studies

    Article • Nature Reviews Neurology, January 2017, Springer Science + Business Media

    Dr Tomas Kalincik

  14. Olfactory ensheathing cells but not fibroblasts reduce the duration of autonomic dysreflexia in spinal cord injured rats

    Article • Autonomic Neuroscience, December 2016, Elsevier

    Dr Tomas Kalincik

  15. Identification of MS patients at highest risk of cognitive impairment using MRI volumetry.

    Article • European Journal of Neurology, November 2016, Wiley

    Dr Tomas Kalincik, Dr. Tomas TU Uher

  16. Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis

    Article • Frontiers in Neurology, November 2016, Frontiers

    Dr Tomas Kalincik

  17. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

    Article • Journal of Neurology Neurosurgery & Psychiatry, September 2016, BMJ

    Dr Tomas Kalincik

  18. Data quality evaluation for observational multiple sclerosis registries

    Article • Multiple Sclerosis Journal, August 2016, SAGE Publications

    Dr Tomas Kalincik

  19. Reporting treatment outcomes in observational data: A fine balance

    Article • Multiple Sclerosis Journal, July 2016, SAGE Publications

    Dr Tomas Kalincik

  20. Combining clinical and MRI markers enhances prediction of 12-year disability in multiple sclerosis.

    Article • Multiple Sclerosis Journal, July 2016, SAGE Publications

    Dr. Tomas TU Uher, Dr Tomas Kalincik

  21. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Article • Multiple Sclerosis Journal, July 2016, SAGE Publications

    Dr Tomas Kalincik

  22. Observational data: Understanding the real MS world

    Article • Multiple Sclerosis Journal, July 2016, SAGE Publications

    Dr Tomas Kalincik

  23. Defining secondary progressive multiple sclerosis

    Article • Brain, July 2016, Oxford University Press (OUP)

    Dr Tomas Kalincik, Dr Cristina M Ramo-Tello

  24. Predictors of long-term disability accrual in relapse-onset multiple sclerosis

    Article • Annals of Neurology, June 2016, Wiley

    Dr Tomas Kalincik

  25. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

    Article • Neurology Clinical Practice, March 2016, Wolters Kluwer Health

    Dr Tomas Kalincik

  26. Defining reliable disability outcomes in multiple sclerosis

    Article • Brain, September 2015, Oxford University Press (OUP)

    Dr Tomas Kalincik

  27. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

    Article • Multiple Sclerosis Journal, July 2015, SAGE Publications

    Dr Tomas Kalincik

  28. Predictors of disease activity in CIS (multiple sclerosis) patients

    Article • European Journal of Neurology, April 2015, Wiley

    Dr Tomas Kalincik, Dr. Tomas TU Uher, Dejan Jakimovski

  29. Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

    Article • JAMA Neurology, April 2015, American Medical Association (AMA)

    Dr Tomas Kalincik

  30. Predictors of disability worsening in clinically isolated syndrome

    Article • Annals of Clinical and Translational Neurology, March 2015, Wiley

    Dr Tomas Kalincik

  31. Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Article • Annals of Clinical and Translational Neurology, February 2015, Wiley

    Dr Tim Spelman, Dr Tomas Kalincik, Prof Alessandra Lugaresi

  32. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

    Article • Annals of Neurology, January 2015, Wiley

    Dr Tomas Kalincik

  33. Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review

    Article • Neuroepidemiology, January 2015, Karger Publishers

    Dr Tomas Kalincik

  34. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

    Article • Multiple Sclerosis Journal, December 2014, SAGE Publications

    Dr Tomas Kalincik

  35. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome

    Article • Journal of Neurology, June 2014, Springer Science + Business Media

    Dr Tomas Kalincik, Dr. Tomas TU Uher

  36. Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis

    Article • European Journal of Neurology, June 2014, Wiley

    Dr Tomas Kalincik

  37. Risk of relapse phenotype recurrence in multiple sclerosis

    Article • Multiple Sclerosis Journal, April 2014, SAGE Publications

    Dr Tomas Kalincik

  38. Fingolimod after natalizumab and the risk of short-term relapse

    Article • Neurology, March 2014, Wolters Kluwer Health

    Dr Tomas Kalincik

  39. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

    Article • Brain, October 2013, Oxford University Press (OUP)

    Dr Tomas Kalincik, Dr. Guglielmo Lucchese

  40. Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis

    Article • Radiology, September 2013, Radiological Society of North America (RSNA)

    Dr Tomas Kalincik

  41. Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis

    Article • PLoS ONE, May 2013, PLOS

    Dr Tomas Kalincik

  42. Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

    Article • American Journal of Neuroradiology, April 2013, American Society of Neuroradiology (ASNR)

    Dr Tomas Kalincik

  43. Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome

    Article • Genes and Immunity, April 2013, Springer Science + Business Media

    Dr Tomas Kalincik

  44. Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study

    Article • PLoS ONE, January 2013, PLOS

    Dr Tomas Kalincik

  45. Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis

    Article • Neurological Research, December 2012, Taylor & Francis

    Dr Tomas Kalincik

  46. Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study

    Article • PLoS ONE, November 2012, PLOS

    Dr Tomas Kalincik

  47. Cross Cultural Validation of The Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

    Article • The Clinical Neuropsychologist, October 2012, Taylor & Francis

    Dr Tomas Kalincik

  48. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort

    Article • Clinical Neurology and Neurosurgery, September 2012, Elsevier

    Dr Tomas Kalincik

  49. Early predictors of non-response to interferon in multiple sclerosis

    Article • Acta Neurologica Scandinavica, March 2012, Wiley

    Dr Tomas Kalincik

  50. Clinical correlates of grey matter pathology in multiple sclerosis

    Article • BMC Neurology, March 2012, Springer Science + Business Media

    Dr Tomas Kalincik

  51. Disturbance of real space navigation in moderately advanced but not in early Huntington's disease

    Article • Journal of the Neurological Sciences, January 2012, Elsevier

    Dr Tomas Kalincik

  52. Corpus Callosum Atrophy – A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study

    Article • European Neurology, January 2012, Karger Publishers

    Dr Tomas Kalincik

  53. Cost of multiple sclerosis in the Czech Republic: The COMS study

    Article • Multiple Sclerosis Journal, September 2011, SAGE Publications

    Dr Tomas Kalincik

  54. Selected changes in spinal cord morphology after T4 transection and olfactory ensheathing cell transplantation

    Article • Autonomic Neuroscience, December 2010, Elsevier

    Dr Tomas Kalincik

  55. Arteriovenous differences of hematological and coagulation parameters in patients with sepsis

    Article • Blood Coagulation & Fibrinolysis, September 2010, Wolters Kluwer Health

    Dr Tomas Kalincik, Dr Miroslav Durila

  56. Heparinase-modified thromboelastography can result in a fibrinolytic pattern

    Article • Anaesthesia, July 2010, Wiley

    Dr Tomas Kalincik, Dr Miroslav Durila

  57. Olfactory ensheathing cells reduce duration of autonomic dysreflexia in rats with high spinal cord injury

    Article • Autonomic Neuroscience, April 2010, Elsevier

    Dr Tomas Kalincik

  58. Discard volume necessary for elimination of heparin flush effect on thromboelastography

    Article • Blood Coagulation & Fibrinolysis, March 2010, Wolters Kluwer Health

    Dr Tomas Kalincik, Dr Miroslav Durila

  59. Local response to cold in rat tail after spinal cord transection

    Article • Journal of Applied Physiology, April 2009, American Physiological Society

    Dr Tomas Kalincik